C4 Therapeutics Inc.

05/16/2022 | Press release | Distributed by Public on 05/16/2022 15:54

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and[...]